semaglutide fda indications Oral Wegovy approved for obesity management by on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) FDA Approves Semaglutide for New

The pattern in patient reviews: those reporting substantial weight loss (10+ pounds in 4 weeks) invariably mention concurrent dietary changes, increased exercise, or use of other medications (metformin, GLP-1 agonists)

Weight-based dosing considerations The standard semaglutide protocol uses fixed doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) regardless of body weight

Lean Muscle Gain As growth hormone and IGF-1 increase, patients often notice a boost in muscle protein synthesis , making it easier to gain lean muscle and recover from strength training

Has high stability

A more is better approach doesnt work with creatine, as your body can only store so much